AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles

[1]  D. Sakkas,et al.  A diagnosis of diminished ovarian reserve does not impact embryo aneuploidy or live birth rates compared to patients with normal ovarian reserve. , 2022, Fertility and sterility.

[2]  Cheng Shi,et al.  The Predictive Levels of Serum Anti-Müllerian Hormone and the Combined Index of the Number of Retrieved Oocytes and Good-Quality Embryos in Advanced-Age Infertile Women , 2022, International journal of endocrinology.

[3]  E. Jungheim,et al.  State-Mandated Insurance Coverage and Preimplantation Genetic Testing in the United States , 2022, Obstetrics and gynecology.

[4]  E. Araújo Júnior,et al.  Association between decreased ovarian reserve and poor oocyte quality , 2021, Obstetrics & gynecology science.

[5]  G. López,et al.  Evaluation of the Anti-Müllerian Hormone and its Association with Embryo Quality in Advanced Reproductive Treatments in a Latin American Population , 2021, JBRA assisted reproduction.

[6]  K. Pantos,et al.  PGT-A: who and when? Α systematic review and network meta-analysis of RCTs , 2021, Journal of Assisted Reproduction and Genetics.

[7]  J. Kawwass,et al.  Pregnancy and Neonatal Outcomes after Transfer of Mosaic Embryos: A Review , 2021, Journal of clinical medicine.

[8]  D. Seifer,et al.  AMH Highly Correlates with Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve Independent of Age. , 2021, The Journal of clinical endocrinology and metabolism.

[9]  D. Seifer.  Connecting the dots between oocyte quantity and quality in diminished ovarian reserve. , 2021, Fertility and sterility.

[10]  C. McCulloch,et al.  Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity. , 2021, Fertility and sterility.

[11]  E. Ginsburg,et al.  The cost-effectiveness of preimplantation genetic testing for aneuploidy in the United States: An analysis of cost and birth outcomes from 158,665 in vitro fertilization cycles. , 2021, American journal of obstetrics and gynecology.

[12]  H. Cuckle,et al.  Maternal age in the epidemiology of common autosomal trisomies , 2020, Prenatal diagnosis.

[13]  Clinical management of mosaic results from preimplantation genetic testing for aneuploidy (PGT-A) of blastocysts: a committee opinion. , 2020, Fertility and sterility.

[14]  P. Patrizio,et al.  The 2019 PGDIS position statement on transfer of mosaic embryos within a context of new information on PGT-A , 2020, Reproductive Biology and Endocrinology.

[15]  D. Seifer,et al.  Anti-Müllerian hormone as a qualitative marker - or just quantity? , 2020, Current opinion in obstetrics & gynecology.

[16]  R. Tal,et al.  Anti-Müllerian Hormone and Its Predictive Utility in Assisted Reproductive Technologies Outcomes , 2019, Clinical obstetrics and gynecology.

[17]  J. Kawwass,et al.  National mosaic embryo transfer practices: a survey , 2018, American journal of obstetrics and gynecology.

[18]  Xiao-yan Liang,et al.  Basal Serum Anti-Müllerian Hormone Level as a Predictor of Clinical Outcomes in Freezing-all Embryo Transfer Program , 2018, Current Medical Science.

[19]  G. Patounakis,et al.  Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance , 2018, Human reproduction.

[20]  V. Baker,et al.  Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. , 2018, Fertility and sterility.

[21]  D. Braga,et al.  The predictive value of serum concentrations of anti-Müllerian hormone for oocyte quality, fertilization, and implantation , 2017, JBRA assisted reproduction.

[22]  D. Seifer,et al.  Ovarian reserve testing: a user's guide , 2017, American journal of obstetrics and gynecology.

[23]  C. Simón,et al.  In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. , 2017, Fertility and sterility.

[24]  V. Baker,et al.  Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. , 2016, Fertility and sterility.

[25]  V. Genro,et al.  AMH as a Prognostic Factor for Blastocyst Development. , 2015, JBRA Assisted Reproduction.

[26]  L. Rienzi,et al.  Reduction of multiple pregnancies in the advanced maternal age population after implementation of an elective single embryo transfer policy coupled with enhanced embryo selection: pre- and post-intervention study , 2015, Human reproduction.

[27]  D. Seifer,et al.  Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. , 2015, Fertility and sterility.

[28]  D. Seifer,et al.  Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. , 2014, American journal of obstetrics and gynecology.

[29]  S. Iliodromiti,et al.  The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. , 2014, Human reproduction update.

[30]  M. Eijkemans,et al.  Anti-Mullerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause. , 2014, Human reproduction.

[31]  W. Schoolcraft,et al.  Association of Abnormal Ovarian Reserve Parameters With a Higher Incidence of Aneuploid Blastocysts , 2013, Obstetrics and gynecology.

[32]  J. Forman,et al.  Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age. , 2013, Human reproduction.

[33]  C. Racowsky,et al.  Testing and interpreting measures of ovarian reserve: a committee opinion. , 2020, Fertility and sterility.

[34]  L. Nardo,et al.  The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[35]  A. Volpe,et al.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). , 2010, Human reproduction update.

[36]  F. Broekmans,et al.  Ovarian aging: mechanisms and clinical consequences. , 2009, Endocrine reviews.

[37]  H. Abdalla,et al.  Relationship between women's age and basal follicle-stimulating hormone levels with aneuploidy risk in in vitro fertilization treatment. , 2008, Fertility and sterility.

[38]  G. Zielhuis,et al.  Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. , 2007, Fertility and sterility.

[39]  G. Lambert-Messerlian,et al.  Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. , 2006, Human reproduction.

[40]  L. Gianaroli,et al.  Fertility and ageing. , 2005, Human reproduction update.

[41]  D. Seifer,et al.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. , 2002, Fertility and sterility.